Investing.com - Avadel Pharma reported on Monday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-0.45 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.4329 on revenue of $0.00.
Avadel Pharma shares are down 48.27% from the beginning of the year and are trading at $4.180 , down-from-52-week-high.They are under-performing the Nasdaq which is down 24.34% from the start of the year.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by UnitedHealth on Thursday, April 14, 2022, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on Tuesday, April 19, 2022 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar